Table 2 Comparison of clinical characteristics between patients with CRKP-BSI and CSKP-BSI
Variable | The total (N = 706) | CRKP (N = 212) | CSKP (N = 494) | P value |
|---|---|---|---|---|
Male, n, (%) | 472 (66.9) | 138 (65.1) | 334 (67.6) | 0.515 |
Age(y), mean ± SD | 58.9 ± 16.0 | 60.8 ± 16.0 | 58.1 ± 16.2 | 0.147 |
Comorbidities-No., % | ||||
 Congestive heart failure | 96 (13.6) | 22 (10.4) | 74 (15.0) | 0.102 |
 Cerebrovascular disease | 122 (17.3) | 40 (18.9) | 82 (16.6) | 0.465 |
 Chronic lung diseases | 146 (20.7) | 52 (24.5) | 94 (19.0) | 0.098 |
 Hepatobiliary and pancreatic diseases | 130 (18.4) | 30 (14.2) | 100 (20.2) | 0.056 |
 Kidney diseases | 172 (24.4) | 56 (26.4) | 116 (23.5) | 0.405 |
 Hematologic malignancy | 84 (11.9) | 54 (25.5) | 30 (6.1) | < 0.001 |
 Solid tumor | 118 (16.7) | 40 (18.9) | 78 (15.8) | 0.315 |
 Solid organ transplantation | 49 (6.9) | 19 (9.0) | 30 (6.1) | 0.166 |
 Diabetes mellitus | 140 (19.8) | 36 (17.0) | 104 (21.1) | 0.214 |
 Immune diseases | 42 (5.9) | 18 (8.5) | 24 (4.9) | 0.061 |
 Charlson comorbidity index ≥ 3 | 348 (49.3) | 112 (52.8) | 236 (47.8) | 0.218 |
Pre-infection healthcare interventions-No., % | ||||
 Enemac | 52 (7.4) | 18 (8.5) | 34 (6.9) | 0.453 |
 Nasogastric catheterb | 174 (24.6) | 46 (21.7) | 128 (25.9) | 0.234 |
 Urinary catheterb | 254 (36.0) | 82 (38.7) | 172 (34.8) | 0.327 |
 Surgical drainb | 104 (14.7) | 38 (17.9) | 66 (13.4) | 0.117 |
 Central venous catheterb | 190 (26.9) | 64 (30.2) | 126 (25.5) | 0.198 |
 Peripheral arterial catheterb | 65 (9.2) | 26 (12.3) | 39 (7.9) | 0.066 |
 Blood purificationb | 72 (10.2) | 28 (13.2) | 44 (8.9) | 0.083 |
 Tracheal cannulab | 288 (40.8) | 91 (42.9) | 197 (39.9) | 0.450 |
 Tracheostomyb | 54 (7.6) | 20 (9.4) | 34 (6.9) | 0.242 |
 Mechanical ventilationc | 182 (25.8) | 64 (30.2) | 118 (23.9) | 0.079 |
 Gastroscopyc | 15 (2.1) | 6 (2.8) | 9 (1.8) | 0.394 |
 Colonoscopyc | 6 (0.8) | 2 (0.9) | 4 (0.8) | 0.859 |
 Bronchoscopyc | 78 (11.0) | 24 (11.3) | 54 (10.9) | 0.880 |
 Sputum suctionb | 356 (50.4) | 115 (54.2) | 241 (48.8) | 0.184 |
 Thoracentesisb | 56 (7.9) | 21 (9.9) | 35 (7.1) | 0.204 |
 Abdominocentesisb | 35 (5.0) | 12 (5.7) | 23 (4.7) | 0.573 |
 Bone marrow punctureb | 91 (12.9) | 33 (15.6) | 58 (11.7) | 0.164 |
 Lumbar punctureb | 68 (9.6) | 25 (11.8) | 43 (8.7) | 0.202 |
 Previous surgeryb | 140 (19.8) | 58 (27.4) | 82 (16.6) | 0.001 |
 Parenteral nutritionb | 237 (33.6) | 77 (36.3) | 160 (32.4) | 0.311 |
 Previous hospitalizationa | 378 (53.5) | 134 (63.2) | 244 (49.4) | 0.001 |
Previous treatments administeredb-No., % | ||||
 Corticosteroids | 138 (19.5) | 52 (24.5) | 86 (17.4) | 0.029 |
 Chemotherapy or radiotherapy | 150 (21.2) | 40 (18.9) | 110 (22.3) | 0.311 |
 Inadequate empirical antibiotic therapy | 261 (37.0) | 96 (45.3) | 165 (33.4) | 0.003 |
 Previous use of antibiotics | ||||
  Carbapenems | 218 (30.9) | 68 (32.1) | 150 (30.4) | 0.652 |
  Glycopeptides | 144 (20.4) | 48 (22.6) | 96 (19.4) | 0.332 |
  Quinolones | 227 (32.2) | 74 (34.9) | 153 (31.0) | 0.305 |
  3rd/4th generation cephalosporins | 102 (14.4) | 38 (17.9) | 64 (13.0) | 0.085 |
  1st/2nd generation cephalosporins | 86 (12.2) | 25 (11.8) | 61 (12.3) | 0.836 |
  Penicillins | 35 (5.0) | 8 (3.8) | 27 (5.5) | 0.342 |
  β-lactamase inhibitor | 308 (43.6) | 101 (47.6) | 207 (41.9) | 0.159 |
  Aminoglycosides | 27 (3.8) | 12 (5.7) | 15 (3.0) | 0.096 |
  Linezolid | 41 (5.8) | 14 (6.6) | 27 (5.5) | 0.553 |
  Tigecycline | 77 (10.9) | 28 (13.2) | 49 (9.9) | 0.199 |
  Daptomycin | 8 (1.1) | 2 (0.9) | 6 (1.2) | 0.755 |
  Nitroimidazoles | 32 (4.5) | 13 (6.1) | 19 (3.8) | 0.181 |
Source of BSI-No., % | ||||
 Primary | 408 (57.8) | 112 (52.8) | 296 (59.9) | 0.080 |
 KP detection in samples from other sites | 348 (49.3) | 116 (54.7) | 232 (47.0) | 0.059 |
  Pulmonary | 166 (23.5) | 66 (31.7) | 100 (20.1) | 0.001 |
  Pleural effusion | 16 (2.3) | 6 (2.8) | 10 (2.0) | 0.510 |
  Pancreaticobiliary tract infection | 40 (5.7) | 14 (6.6) | 26 (5.3) | 0.480 |
  Live abscess | 30 (4.2) | 12 (5.7) | 18 (3.6) | 0.223 |
  Urinary tract infection | 35 (5.0) | 11 (5.2) | 24 (4.9) | 0.853 |
  Intestinal infection | 26 (3.7) | 6 (2.8) | 20 (4.0) | 0.431 |
  Intra-abdominal infection | 17 (2.4) | 5 (2.4) | 12 (2.4) | 0.955 |
  Skin infection | 12 (1.7) | 4 (1.9) | 8 (1.6) | 0.801 |
  Cerebrospinal fluid | 6 (0.8) | 2 (0.9) | 4 (0.8) | 0.859 |
Ward at the onset of BSI-No., % | ||||
 Intensive care units | 300 (42.5) | 120 (56.6) | 180 (36.4) | < 0.001 |
 Medical wards | 232 (32.9) | 54 (25.5) | 178 (36.0) | 0.006 |
 Surgical wards | 170 (24.1) | 38 (17.9) | 132 (26.7) | 0.012 |
Severity at BSI onset-No., % | ||||
 APACHE II score > 15 | 240 (34.0) | 86 (40.6) | 154 (31.2) | 0.016 |
 Severe sepsis/septic shock | 244 (34.6) | 88 (41.5) | 156 (31.6) | 0.011 |
 Outcome-No., % | ||||
 28-day mortality | 190 (26.9) | 90 (42.5) | 100 (20.2) | < 0.001 |